淋巴瘤中免疫检查点阻断的疗效及反应生物标志物：一项叙述性综述
Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review.
作者信息
Perdikis-Prati Sarah, Sheikh Semira, Bouroumeau Antonin, Lang Noémie
机构信息
Department of Oncology, Geneva University Hospital, 1205 Geneva, Switzerland.
Department of Hematology, Universitätsspital Basel, 4031 Basel, Switzerland.
出版信息
Biomedicines. 2023 Jun 15;11(6):1720. doi: 10.3390/biomedicines11061720.
Immune checkpoint blockade (ICB) has revolutionized the prognosis of several advanced-stage solid tumors. However, its success has been far more limited in hematological malignancies and is mostly restricted to classical Hodgkin lymphoma (cHL) and primary mediastinal B cell lymphoma (PMBCL). In patients with non-Hodgkin lymphoma (NHL), response to PD-1/PD-L1 ICB monotherapy has been relatively limited, although some subtypes are more sensitive than others. Numerous predictive biomarkers have been investigated in solid malignancies, such as PD-L1 expression, tumor mutational burden (TMB) and microsatellite instability (MSI), among others. This review aims to appraise the current knowledge on PD-1/PD-L1 ICB efficacy in lymphoma when used either as monotherapy or combined with other agents, and describes potential biomarkers of response in this specific setting.
免疫检查点阻断（ICB）彻底改变了几种晚期实体瘤的预后。然而，其在血液系统恶性肿瘤中的成功却极为有限，主要局限于经典型霍奇金淋巴瘤（cHL）和原发性纵隔B细胞淋巴瘤（PMBCL）。在非霍奇金淋巴瘤（NHL）患者中，尽管某些亚型比其他亚型更敏感，但对PD-1/PD-L1 ICB单药治疗的反应相对有限。在实体恶性肿瘤中已经研究了许多预测性生物标志物，如PD-L1表达、肿瘤突变负荷（TMB）和微卫星不稳定性（MSI）等。本综述旨在评估目前关于PD-1/PD-L1 ICB在淋巴瘤中作为单药治疗或与其他药物联合使用时的疗效的知识，并描述在这一特定情况下潜在的反应生物标志物。
Zotero 插件